Clinical Trial Update: Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low concentration estriol (0.005%) for efficacy and safety in postmenopausal vaginal atrophy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaginal Atrophy

Snippet

Sponsor: Italfarmaco S.A | Conditions: Vaginal Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2020-12-11